Rangwala Reshma 4
4 · Karyopharm Therapeutics Inc. · Filed Apr 24, 2023
Insider Transaction Report
Form 4
Rangwala Reshma
EVP & Chief Medical Officer
Transactions
- Sale
Common Stock
2023-04-20$4.03/sh−115$463→ 164,885 total - Sale
Common Stock
2023-04-20$4.05/sh−6,655$26,953→ 158,230 total
Footnotes (1)
- [F1]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.